Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Associazione Qol-one
The present study aims to compare the efficacy of postremission maintenance therapy with 5-Aza versus best supportive care (BSC) in a cohort of AML patients aged \>60 years, who have achieved CR following conventional induction ('3+7') and consolidation chemotherapy to evaluate 2 an 5 year post-remission rates of Overall Survival and disease free survival between two arms
Age
61–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age 61 years or more
2. Newly diagnosed AML with \> 30% myeloid marrow blasts, either "de novo" or evolving from a MDS not previously treated with chemotherapeutic agents.
3. Absence of central nervous system involvement
4. No contraindications for intensive chemotherapy, defined as:
1. prior congestive heart failure requiring treatment and/or left ventricular systolic ejection fraction below the normal range;
2. a creatinine or bilirubin level more than twice the upper limit of normal, except if AML-related;
3. a Performance Status (PS) score of \> 2;
4. uncontrolled severe infection.
5. Informed consent.
You may not be if
1. Age ≤ 60 years
2. Newly diagnosed AML with \< 30% myeloid marrow blasts
3. Previously treated AML
4. Central nervous system involvement
5. Prior congestive heart failure requiring treatment and/or left ventricular systolic ejection fraction below the normal range;
6. A creatinine or bilirubin level more than twice the upper limit of normal, except if AML-related;
7. A PS score of \> 2;
8. Uncontrolled severe infection.
Clareo Health | Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients
